Travere Therapeutics (TVTX) Change in Acquisitions & Divestments (2013 - 2026)

Travere Therapeutics has reported Change in Acquisitions & Divestments for 14 years, with the latest figure at $48.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 8.23% year-over-year to $48.8 million; the trailing twelve-month figure through Mar 2026 stood at $319.2 million (up 19.06% YoY), and the FY2025 full-year result was $323.6 million, down 0.84% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $48.8 million, down from $82.4 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $152.6 million in Q2 2022, with the low at $48.8 million in Q1 2026.
• Historically, Change in Acquisitions & Divestments has averaged $83.3 million across 5 years, with a median of $82.4 million in 2025.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments slumped 57.54% — and 2025, when it soared 96.29%.
• Travere Therapeutics' Change in Acquisitions & Divestments stood at $52.4 million in 2022, then retreated by 4.55% to $50.0 million in 2023, then increased by 10.1% to $55.0 million in 2024, then surged by 49.72% to $82.4 million in 2025, then slumped by 40.81% to $48.8 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $48.8 million (Q1 2026), $82.4 million (Q4 2025), and $106.6 million (Q3 2025), per Business Quant data.